Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons

Haya Ascher-Svanum1, William S Montgomery2, David P McDonnell3, Kristina A Coleman4, Peter D Feldman11Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly Australia Pty Ltd, West Ryde, New South Wales, Australia; 3Eli Lilly and Company, Cork, Ireland; 4OptumInsight,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ascher-Svanum H, Montgomery WS, McDonnell DP, Coleman KA, Feldman PD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Dove Medical Press 2012-05-01
coleção:	International Journal of General Medicine
Acesso em linha:	http://www.dovepress.com/treatment-completion-rates-with-olanzapine-long-acting-injection-versu-a9821
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!